1
|
Verma S, Paliwal S. Recent Developments and Applications of Biocatalytic and Chemoenzymatic Synthesis for the Generation of Diverse Classes of Drugs. Curr Pharm Biotechnol 2024; 25:448-467. [PMID: 37885105 DOI: 10.2174/0113892010238984231019085154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Revised: 08/26/2023] [Accepted: 09/19/2023] [Indexed: 10/28/2023]
Abstract
Biocatalytic and chemoenzymatic biosynthesis are powerful methods of organic chemistry that use enzymes to execute selective reactions and allow the efficient production of organic compounds. The advantages of these approaches include high selectivity, mild reaction conditions, and the ability to work with complex substrates. The utilization of chemoenzymatic techniques for the synthesis of complicated compounds has lately increased dramatically in the area of organic chemistry. Biocatalytic technologies and modern synthetic methods are utilized synergistically in a multi-step approach to a target molecule under this paradigm. Chemoenzymatic techniques are promising for simplifying access to essential bioactive compounds because of the remarkable regio- and stereoselectivity of enzymatic transformations and the reaction diversity of modern organic chemistry. Enzyme kits may include ready-to-use, reproducible biocatalysts. Its use opens up new avenues for the synthesis of active therapeutic compounds and aids in drug development by synthesizing active components to construct scaffolds in a targeted and preparative manner. This study summarizes current breakthroughs as well as notable instances of biocatalytic and chemoenzymatic synthesis. To assist organic chemists in the use of enzymes for synthetic applications, it also provides some basic guidelines for selecting the most appropriate enzyme for a targeted reaction while keeping aspects like cofactor requirement, solvent tolerance, use of whole cell or isolated enzymes, and commercial availability in mind.
Collapse
Affiliation(s)
- Swati Verma
- Department of Pharmacy, ITS College of Pharmacy, Muradnagar, Ghaziabad, India
- Department of Pharmacy, Banasthali Vidyapith, Banasthali, 304022, Rajasthan, India
| | - Sarvesh Paliwal
- Department of Pharmacy, Banasthali Vidyapith, Banasthali, 304022, Rajasthan, India
| |
Collapse
|
2
|
Chen Y, Jo J, Hernandez E, Wang H, Bernardoni F. Biocatalytic cascade process of islatravir: Analytical and regulatory control strategy of minor enantiomer. J Pharm Biomed Anal 2023; 234:115536. [PMID: 37343454 DOI: 10.1016/j.jpba.2023.115536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 05/16/2023] [Accepted: 06/15/2023] [Indexed: 06/23/2023]
Abstract
Commercial process of islatravir (MK-8591, EFdA) utilizes biocatalytic cascade reactions to construct the ribose moiety of the molecule which bears three chiral centers. However, this biocatalytic process also brought analytical challenges where all stereoisomers and process related compounds are controlled in one isolated intermediate, the final drug substance. A chiral LC method was developed to resolve all those compounds from islatravir and its minor enantiomer by thorough column screening and careful optimization. Detail of designing key method validation components such as method linearity, precision and robustness is discussed, and their results were presented. The method was successfully validated to fulfill various expectation from each individual health authority including FDA, EMA, PMDA, and ANVISA.
Collapse
Affiliation(s)
- Yun Chen
- Analytical Research and Development, MRL, Merck & Co., Inc., Rahway, NJ 07065, USA.
| | - Junyong Jo
- Analytical Research and Development, MRL, Merck & Co., Inc., Rahway, NJ 07065, USA.
| | - Edgar Hernandez
- Analytical Research and Development, MRL, Merck & Co., Inc., Rahway, NJ 07065, USA
| | - Heather Wang
- Analytical Research and Development, MRL, Merck & Co., Inc., Rahway, NJ 07065, USA
| | - Frank Bernardoni
- Analytical Research and Development, MRL, Merck & Co., Inc., Rahway, NJ 07065, USA
| |
Collapse
|
3
|
Merging enzymatic and synthetic chemistry with computational synthesis planning. Nat Commun 2022; 13:7747. [PMID: 36517480 PMCID: PMC9750992 DOI: 10.1038/s41467-022-35422-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Accepted: 11/30/2022] [Indexed: 12/15/2022] Open
Abstract
Synthesis planning programs trained on chemical reaction data can design efficient routes to new molecules of interest, but are limited in their ability to leverage rare chemical transformations. This challenge is acute for enzymatic reactions, which are valuable due to their selectivity and sustainability but are few in number. We report a retrosynthetic search algorithm using two neural network models for retrosynthesis-one covering 7984 enzymatic transformations and one 163,723 synthetic transformations-that balances the exploration of enzymatic and synthetic reactions to identify hybrid synthesis plans. This approach extends the space of retrosynthetic moves by thousands of uniquely enzymatic one-step transformations, discovers routes to molecules for which synthetic or enzymatic searches find none, and designs shorter routes for others. Application to (-)-Δ9 tetrahydrocannabinol (THC) (dronabinol) and R,R-formoterol (arformoterol) illustrates how our strategy facilitates the replacement of metal catalysis, high step counts, or costly enantiomeric resolution with more elegant hybrid proposals.
Collapse
|
4
|
Gunsch MJ, Schwalm EL, Ouimet CM, Halsey HM, Hamilton SE, Bernardoni F, Jo J. Development and validation of ion-pairing HPLC-CAD chromatography for measurement of Islatravir’s phosphorylated intermediates. J Pharm Biomed Anal 2022; 213:114684. [DOI: 10.1016/j.jpba.2022.114684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2022] [Revised: 02/17/2022] [Accepted: 02/18/2022] [Indexed: 11/30/2022]
|
5
|
Cosgrove SC, Miller GJ. Advances in biocatalytic and chemoenzymatic synthesis of nucleoside analogues. Expert Opin Drug Discov 2022; 17:355-364. [PMID: 35133222 DOI: 10.1080/17460441.2022.2039620] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
INTRODUCTION Nucleoside analogues represent a cornerstone of achievement in drug discovery, rising to prominence particularly in the fields of antiviral and anticancer discovery over the last 60 years. Traditionally accessed using chemical synthesis, a paradigm shift to include the use of biocatalytic synthesis is now apparent. AREAS COVERED Herein, the authors discuss the recent advances using this technology to access nucleoside analogues. Two key aspects are covered, the first surrounding methodology concepts, effectively using enzymes to access diverse nucleoside analogue space and also for producing key building blocks. The second focuses on the use of biocatalytic cascades for de novo syntheses of nucleoside analogue drugs. Finally, recent advances in technologies for effecting enzymatic nucleoside synthesis are considered, chiefly immobilization and flow. EXPERT OPINION Enzymatic synthesis of nucleoside analogues is maturing but has yet to usurp chemical synthesis as a first-hand synthesis technology, with scalability and substrate modification primary issues. Moving forward, tandem approaches that harness expertise across molecular microbiology and chemical synthesis will be vital to unlocking the potential of next generation nucleoside analogue drug discovery.
Collapse
Affiliation(s)
- Sebastian C Cosgrove
- Lennard-Jones Laboratory, School of Chemical and Physical Sciences, Keele University, Keele, Staffordshire, UK.,Centre for Glycoscience Research, Keele University, Keele, Staffordshire, UK
| | - Gavin J Miller
- Lennard-Jones Laboratory, School of Chemical and Physical Sciences, Keele University, Keele, Staffordshire, UK.,Centre for Glycoscience Research, Keele University, Keele, Staffordshire, UK
| |
Collapse
|
6
|
Wang H, Zhong YY, Xiao YC, Chen FE. Chemical and chemoenzymatic stereoselective synthesis of β-nucleosides and their analogues. Org Chem Front 2022. [DOI: 10.1039/d1qo01936h] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
β-Nucleosides are fundamental building blocks of biological systems that are widely used as therapeutic agents for treating cancer and viral infections among others. In the last two years, nucleoside analogues...
Collapse
|
7
|
Simić S, Zukić E, Schmermund L, Faber K, Winkler CK, Kroutil W. Shortening Synthetic Routes to Small Molecule Active Pharmaceutical Ingredients Employing Biocatalytic Methods. Chem Rev 2021; 122:1052-1126. [PMID: 34846124 DOI: 10.1021/acs.chemrev.1c00574] [Citation(s) in RCA: 69] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Biocatalysis, using enzymes for organic synthesis, has emerged as powerful tool for the synthesis of active pharmaceutical ingredients (APIs). The first industrial biocatalytic processes launched in the first half of the last century exploited whole-cell microorganisms where the specific enzyme at work was not known. In the meantime, novel molecular biology methods, such as efficient gene sequencing and synthesis, triggered breakthroughs in directed evolution for the rapid development of process-stable enzymes with broad substrate scope and good selectivities tailored for specific substrates. To date, enzymes are employed to enable shorter, more efficient, and more sustainable alternative routes toward (established) small molecule APIs, and are additionally used to perform standard reactions in API synthesis more efficiently. Herein, large-scale synthetic routes containing biocatalytic key steps toward >130 APIs of approved drugs and drug candidates are compared with the corresponding chemical protocols (if available) regarding the steps, reaction conditions, and scale. The review is structured according to the functional group formed in the reaction.
Collapse
Affiliation(s)
- Stefan Simić
- Institute of Chemistry, University of Graz, NAWI Graz, Heinrichstraße 28, 8010 Graz, Austria
| | - Erna Zukić
- Institute of Chemistry, University of Graz, NAWI Graz, Heinrichstraße 28, 8010 Graz, Austria
| | - Luca Schmermund
- Institute of Chemistry, University of Graz, NAWI Graz, Heinrichstraße 28, 8010 Graz, Austria
| | - Kurt Faber
- Institute of Chemistry, University of Graz, NAWI Graz, Heinrichstraße 28, 8010 Graz, Austria
| | - Christoph K Winkler
- Institute of Chemistry, University of Graz, NAWI Graz, Heinrichstraße 28, 8010 Graz, Austria
| | - Wolfgang Kroutil
- Institute of Chemistry, University of Graz, NAWI Graz, Heinrichstraße 28, 8010 Graz, Austria.,Field of Excellence BioHealth─University of Graz, 8010 Graz, Austria.,BioTechMed Graz, 8010 Graz, Austria
| |
Collapse
|
8
|
Ami EI, Ohrui H. Intriguing Antiviral Modified Nucleosides: A Retrospective View into the Future Treatment of COVID-19. ACS Med Chem Lett 2021; 12:510-517. [PMID: 33854700 PMCID: PMC8040047 DOI: 10.1021/acsmedchemlett.1c00070] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
![]()
Great
pioneers of nucleic acid chemistry had elucidated nucleic
acid functions and structures and developed various antiviral modified
nucleoside drugs. It is possible in theory that antiviral modified
nucleosides prevent viral replication by inhibiting viral polymerases.
However, biological phenomena far exceed our predictions at times.
We describe the characteristics of the approved antiviral modified
nucleosides from an organic chemistry perspective. Also, based on
our experiences and findings through the development of the HIV-1
reverse-transcriptase inhibitor “Islatravir”, we provide
the practical and approximate guidelines for the drug development
of antiviral modified nucleosides against COVID-19.
Collapse
Affiliation(s)
- Ei-ichi Ami
- Medical Affairs Division, Kaken Pharmaceutical Co., Ltd., Toshima-ku, Tokyo 171-0033, Japan
| | - Hiroshi Ohrui
- Research Center for Medicinal Chemistry, Yokohama University of Pharmacy, Yokohama 245-0066, Japan
| |
Collapse
|
9
|
Yoshida Y, Honma M, Kimura Y, Abe H. Structure, Synthesis and Inhibition Mechanism of Nucleoside Analogues as HIV-1 Reverse Transcriptase Inhibitors (NRTIs). ChemMedChem 2021; 16:743-766. [PMID: 33230979 DOI: 10.1002/cmdc.202000695] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2020] [Revised: 10/31/2020] [Indexed: 12/13/2022]
Abstract
Acquired immunodeficiency syndrome (AIDS) is caused by infection with the human immunodeficiency virus (HIV). Although treatments against HIV infection are available, AIDS remains a serious disease that causes many deaths annually. Although a variety of anti-HIV drugs have been synthesized and marketed to treat HIV-infected patients, nucleoside analogue reverse transcriptase inhibitors (NRTIs), which mimic nucleosides, are used extensively and remain a subject of interest to medicinal chemists. However, HIV has acquired drug resistance against NRTIs, and thus the struggle to find novel therapies continues. In this review, we trace the trajectory of NRTIs, focusing on the synthesis, mechanisms of action and applications of NRTIs that have been developed.
Collapse
Affiliation(s)
- Yuki Yoshida
- Graduate School of Science, Department of Chemistry, Nagoya University Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Masakazu Honma
- Nucleic Acid Medicine Research Laboratories, Research Functions Unit, R&D Division, Kyowa Kirin Co., Ltd., 3-6-6, Asahi-machi, Machida-shi, >, Tokyo, 194-8533, Japan
| | - Yasuaki Kimura
- Graduate School of Science, Department of Chemistry, Nagoya University Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Hiroshi Abe
- Graduate School of Science, Department of Chemistry, Nagoya University Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan.,Research Center for Materials Science, Nagoya University Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan.,CREST, Japan Science and Technology Agency, 7, Gobancho, Chiyoda-ku, Tokyo, 102-0076, Japan.,Institute for Glyco-core Research (iGCORE), Nagoya University Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| |
Collapse
|
10
|
Chen C, Hu X, Wang C, Lan W, Wu X, Cao C. Structure- and Mechanism-Based Research Progress of Anti-acquired Immune Deficiency Syndrome Drugs. CHINESE J ORG CHEM 2021. [DOI: 10.6023/cjoc202012036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
11
|
McDonald MA, Salami H, Harris PR, Lagerman CE, Yang X, Bommarius AS, Grover MA, Rousseau RW. Reactive crystallization: a review. REACT CHEM ENG 2021. [DOI: 10.1039/d0re00272k] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Reactive crystallization is not new, but there has been recent growth in its use as a means of improving performance and sustainability of industrial processes.
Collapse
Affiliation(s)
- Matthew A. McDonald
- School of Chemical and Biomolecular Engineering
- Georgia Institute of Technology
- Atlanta
- USA
| | - Hossein Salami
- School of Chemical and Biomolecular Engineering
- Georgia Institute of Technology
- Atlanta
- USA
| | - Patrick R. Harris
- School of Chemical and Biomolecular Engineering
- Georgia Institute of Technology
- Atlanta
- USA
| | - Colton E. Lagerman
- School of Chemical and Biomolecular Engineering
- Georgia Institute of Technology
- Atlanta
- USA
| | - Xiaochuan Yang
- Office of Pharmaceutical Quality
- Center for Drug Evaluation and Research
- U.S. Food and Drug Administration
- Silver Spring
- USA
| | - Andreas S. Bommarius
- School of Chemical and Biomolecular Engineering
- Georgia Institute of Technology
- Atlanta
- USA
| | - Martha A. Grover
- School of Chemical and Biomolecular Engineering
- Georgia Institute of Technology
- Atlanta
- USA
| | - Ronald W. Rousseau
- School of Chemical and Biomolecular Engineering
- Georgia Institute of Technology
- Atlanta
- USA
| |
Collapse
|
12
|
Ren S, Huffman MA, Whittaker AM, Yang H, Nawrat CC, Waterhouse DJ, Maloney KM, Strotman NA. Synthesis of Isotopically Labeled Anti-HIV Nucleoside Islatravir through a One-Pot Biocatalytic Cascade Reaction. Org Process Res Dev 2020. [DOI: 10.1021/acs.oprd.0c00476] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Sumei Ren
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Mark A. Huffman
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Aaron M. Whittaker
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Hao Yang
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Christopher C. Nawrat
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - David J. Waterhouse
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Kevin M. Maloney
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Neil A. Strotman
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| |
Collapse
|
13
|
Patel NR, Huffman MA, Wang X, Ding B, McLaughlin M, Newman JA, Andreani T, Maloney KM, Johnson HC, Whittaker AM. Five-Step Enantioselective Synthesis of Islatravir via Asymmetric Ketone Alkynylation and an Ozonolysis Cascade. Chemistry 2020; 26:14118-14123. [PMID: 32710473 DOI: 10.1002/chem.202003091] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2020] [Revised: 07/20/2020] [Indexed: 11/10/2022]
Abstract
A 5-step enantioselective synthesis of the potent anti-HIV nucleoside islatravir is reported. The highly efficient route was enabled by a novel enantioselective alkynylation of an α,β-unsaturated ketone, a unique ozonolysis-dealkylation cascade in water, and an enzymatic aldol-glycosylation cascade.
Collapse
Affiliation(s)
- Niki R Patel
- Department of Process Research and Development, MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA
| | - Mark A Huffman
- Department of Process Research and Development, MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA
| | - Xiao Wang
- Department of Process Research and Development, MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA
| | - Bangwei Ding
- Department of Process Research and Development, MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA
| | - Mark McLaughlin
- Department of Process Research and Development, MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA
| | - Justin A Newman
- Department of Process Research and Development, MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA
| | - Teresa Andreani
- Department of Process Research and Development, MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA
| | - Kevin M Maloney
- Department of Process Research and Development, MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA
| | - Heather C Johnson
- Department of Process Research and Development, MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA
| | - Aaron M Whittaker
- Department of Process Research and Development, MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA
| |
Collapse
|
14
|
Affiliation(s)
- Gavin J Miller
- Lennard-Jones Laboratory, School of Chemical and Physical Sciences, Keele University, Keele, Staffordshire ST5 5BG, UK.
| |
Collapse
|